ArticleJournal of translational medicine2026
Low-dose 5-hydroxymethylfurfural mitigates radiation -induced intestinal toxicity via HIF2α-driven IL22/STAT3 signaling enhancement.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIonizing radiation (IR)-induced intestinal injury limits the efficacy of radiotherapy for abdominal/pelvic malignancies, and there are few effective preventive measures. 5-Hydroxymethylfurfural (5-HMF), a bioactive compound abundant in heat-processed foods and herbal decoctions, has shown therapeutic benefits in inflammatory diseases, yet its role in IR-induced intestinal damage remains unclear.
methodsC57BL/6 male mice (n = 15~17/group) were administered intraperitoneal vehicle, low-dose (50 mg/kg/day), or high-dose (200 mg/kg/day) 5-HMF for 7 days prior to 8–10 Gy of whole-body irradiation (WBI) or total abdominal irradiation (TAI). Assessments included survival, weight recovery, intestinal permeability, crypt survival, as well as proliferation and apoptosis of intestinal stem cells (ISCs). Mechanistic investigations utilized RNA sequencing of crypts, organoid cultures, dual luciferase assays, and pharmacological hypoxia-inducible factor-2α (HIF-2α) inhibition (PT-2385) to explore the radioprotective mechanisms of 5-HMF.
resultsCompared with the control group or high-dose group, low-dose 5-HMF significantly improved survival, accelerated weight recovery, and enhanced crypt regeneration. It promoted ISCs proliferation while inhibiting apoptosis. Mechanistically, 5-HMF stabilized HIF-2α, which bound to hypoxia-response elements (HREs) in the Interleukin-22 receptor-1 (IL22R1) promoter, thereby upregulating IL22R1 expression and amplifying IL22-dependent signal transducer and activator of transcription 3 (STAT3) phosphorylation. Importantly, PT-2385-mediated HIF-2α inhibition abolished the effects of 5-HMF on IL22R1/STAT3 and its radioprotective role both in vivo and in organoids.
conclusionsLow-dose 5-HMF protects against IR-induced intestinal injury by stabilizing HIF-2α to enhance IL22/STAT3 signaling and drive ISC-mediated epithelial regeneration, identifying it as a promising dietary-derived radioprotectant for such damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.